Tau protein, A beta 42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies by Mollenhauer, Brit et al.
Original Research Article
Dement Geriatr Cogn Disord 2005;19:164–170
DOI: 10.1159/000083178
Tau Protein, Aß42 and S-100B Protein
in Cerebrospinal Fluid of Patients with
Dementia with Lewy Bodies
Brit Mollenhauera Lukas Cepeka Mirko Biblb Jens Wiltfangd
Walter J. Schulz-Schaefferc Barbara Ciesielczyka Manuela Neumanne
Petra Steinackerb Hans A. Kretzschmare Sigrid Posera
Claudia Trenkwalderf Markus Ottoa
Departments of aNeurology, bPsychiatry and cNeuropathology, Georg August University Göttingen, Göttingen,
dDepartment of Psychiatry, Friedrich Alexander University Erlangen/Nuremberg, Erlangen, eDepartment of
Neuropathology, Ludwig Maximilians University Munich, Munich, and fGeorg August University Göttingen,
Paracelsus-Elena-Klinik, Kassel, Germany 
Accepted: June 18, 2004
Published online: January 5, 2005
Dr. Brit Mollenhauer
Neurologische Klinik und Poliklinik, Georg-August-Universität Göttingen
Robert-Koch-Strasse 40, DE–37075 Göttingen (Germany)
Tel. +49 551 39 8404, Fax +49 551 39 14449
E-Mail bmollenhauer@med.uni-goettingen.de
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 2005 S. Karger AG, Basel
1420–8008/05/0193–0164$22.00/0
Accessible online at:
www.karger.com/dem
The study was supported in part by a grant from the Bundesminis-
terium für Gesundheit, Berlin, Germany, to Drs. M.O. and S.P.
Key Words
Dementia with Lewy bodies W Alzheimer’s disease W
Cerebrospinal fluid W Tau protein W Aß42 W S-100B
protein W Parkinson’s disease W Laboratory marker
Abstract
The intra vitam diagnosis of dementia with Lewy bodies
(DLB) is still based on clinical grounds. So far no techni-
cal investigations have been available to support this
diagnosis. As for tau protein and ß-amyloid(1–42) (Aß42),
promising results for the diagnosis of Alzheimer’s dis-
ease (AD) have been reported; we evaluated these mark-
ers and S-100B protein in cerebrospinal fluid (CSF), using
a set of commercially available assays, of 71 patients
with DLB, 67 patients with AD and 41 nondemented con-
trols (NDC) for their differential diagnostic relevance.
Patients with DLB showed significantly lower tau protein
values compared to AD but with a high overlap of values.
More prominent differences were observed in the com-
parison of DLB patients with all three clinical core fea-
tures and AD patients. Aß42 levels were decreased in the
DLB and AD groups versus NDC, without significant sub-
group differences. S-100B levels were not significantly
different between the groups. Tau protein levels in CSF
may contribute to the clinical distinction between DLB
and AD, but the value of the markers is still limited espe-
cially due to mixed pathology. We conclude that more
specific markers have to be established for the differenti-
ation of these diseases.
Copyright © 2005 S. Karger AG, Basel
Introduction 
Dementia with Lewy bodies (DLB) is the second most
common type of dementia. A definite diagnosis of DLB
can only be made on the basis of neuropathology [1].
As DLB patients often suffer from neuroleptic sensi-
tivity [2], there is a need to improve clinical diagnosis of
DLB to prevent these patients from receiving the wrong
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medication. For Alzheimer’s disease (AD), a typical cere-
brospinal fluid (CSF) pattern of ß-amyloid(1–42) (Aß42)
and tau protein was postulated. A decrease in Aß42 and
an increase in tau protein levels have been found in most
of the studies [3–6]. Total tau protein, the main structural
component of neurofibrillary pathology, is assumed to be
a marker of neuronal damage in CSF [7, 8], whereas Aß42
is the main component of AD plaques [3–5].
Elevated levels of the astroglial marker S-100B protein
have been observed in acute neurological disease and pos-
sibly indicate damage to astroglial cells in these diseases
[9]. Elevated levels of S-100B have also been reported in
neurodegenerative diseases like AD [10], frontotemporal
dementia [11, 12] and amyotrophic lateral sclerosis [13].
High levels were reported in Creutzfeldt-Jakob disease
and could even be seen in serum samples [14]. In these
cases raised levels are considered to represent astroglial
activation. Up to now no data has been available for the
differential diagnostic value of S-100B protein in DLB
patients.
For DLB, decreased Aß42 and normal tau levels were
reported in small groups of clinically diagnosed patients
[15, 16], but this could not be verified in selected patients
diagnosed post mortem [17]. We have now evaluated tau
protein, Aß42 and S-100B protein in a larger group of
patients with DLB, AD and in nondemented controls
(NDC) to evaluate whether these markers will help to dif-
ferentiate between AD and DLB.
Materials and Methods
Patients with DLB 
The group of DLB patients comprised 2 ‘definite’ cases, 63 ‘prob-
able’ cases and 6 cases with Parkinson’s disease dementia (PDD).
Clinical records from all patients were analyzed according to the clin-
ical criteria of McKeith et al. [1]. At least two of the core symptoms
(fluctuating cognitive decline, extrapyramidal signs, and visual hallu-
cinations) are required for the diagnosis of ‘probable’ DLB. All cases
included fulfilled the criteria for at least ‘probable DLB’. Twenty-
three patients presented with two (group DLB-II) and 48 patients
with all three core features (group DLB-III). All patients were hospi-
talized at least several days for the documentation of fluctuating cog-
nition. Dementia was supported either by Mini Mental Status Exam-
ination (MMSE) [18] or extensive neuropsychological testing and
medical history given by relatives. In 22 patients with DLB, MMSE
was performed at the time of lumbar puncture. Hallucinations and
parkinsonism could not be attributed to medication in all patients
that were included. If parkinsonism had been present for a long time
(more than 1 year) before dementia was diagnosed, such patients
were classified according the established criteria as PDD (n = 6). The
other 65 cases were designated ‘probable’ DLB. All patients under-
went brain imaging to exclude other diseases. Risk factors for vascu-
lar lesions were recorded.
In 2 cases, clinical diagnosis was confirmed by neuropathological
examination using paraffin-embedded formalin-fixed brain tissue
and immunochemistry. Distribution of Lewy bodies and frequency
were evaluated on alpha-synuclein immunostains according to the
consensus guidelines for the pathologic diagnosis of DLB [1].
Patients with AD 
Additionally, we analyzed 67 AD patients and 41 nondemented
controls. Diagnosis of AD was made according to the NINCDS-
ADRDA work group criteria [19]. None of the AD patients suffered
from hallucinations or extrapyramidal signs. All included patients
were at least classified as ‘probable’ AD. Three cases of this group
were neuropathologically verified using paraffin-embedded forma-
lin-fixed brain tissue and immunochemistry. 
Dementia was also diagnosed either with MMSE or extensive
neuropsychological testing and history given by the relatives. In 45
patients with AD, MMSE was performed at the time of lumbar punc-
ture. All patients underwent brain imaging to exclude other diseases.
Risk factors for vascular lesions were recorded.
Patients without Dementia 
The NDC group (n = 41) consisted of patients with depression
(n = 14), acute psychosis (n = 5), old cerebral ischemic lesions (n = 5),
radicular syndromes (n = 3), alcoholic delirium (n = 2), multiple scle-
rosis (n = 2) and 1 patient each with carpal tunnel syndrome, shoul-
der-hand syndrome, schizophrenia, diabetic neuropathy, myopathy,
epileptic seizure, hydrocephalus, neuritis vestibularis, transient mye-
litis, and articular rheumatism.
Age at the time of lumbar puncture, sex distribution, duration of
disease and MMSE scores of these groups are given in table 1.
Tau Protein, Aß42 and S-100B Protein 
Samples of all groups were obtained by lumbar puncture. Ali-
quots for Aß42 and tau protein were stored at B4°C and analyzed
within 2 days. Aliquots for S-100B protein were stored at –80°C
until measurement.
All samples were analyzed using commercially available assays
[4, 14, 20–22] (tau protein and Aß42: Innotest hTAU Antigen and
Innotest ß-Amyloid(1–42), Innogenetics, Ghent, Belgium; S-100B pro-
tein: Sangtec Medical, Bromma, Sweden). In most reports, normal
levels for tau protein were below 450 pg/ml [4–7]. Aß42 should be
above 450 pg/ml in nondemented patients [3–6] and S-100B levels
were below 2 ng/ml in control CSF samples [14, 22].
Tau protein was analyzed in 179 cases. Aß42 levels were deter-
mined in 173 patients and S-100B protein was measured in 113 CSF
samples (table 2).
Statistical Analysis 
The distribution of CSF marker levels between subgroups of the
study population was compared by nonparametric rank tests (for two
groups: Wilcoxon-Mann-Whitney U test, for more than two groups:
Kruskal-Wallis test).
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Table 1. Epidemiological data, MMSE score and clinical classification
DLB AD NDC
Age at the time of lumbar puncture1, years 50–89
(median: 72)
45–86 
(median: 66)
45–56 years
(median: 51 years)
Sex (m:f) 40:31 23:44 15:26
Duration of disease2, months 1–180 
(median: 16.5)
6–80 
(median: 24)
not applicable
MMSE score2 11–25
(median: 16.5)
1–26
(median: 17.5)
not applicable
Exact diagnosis 63 probable DLB
6 PDD
2 definite DLB
64 probable AD
3 definite AD
see text
1 p ! 0.001 between NDC and AD/DLB.
2 Before lumbar puncture.
Table 2. Overview of analysis of markers and groups
DLB
median range n
AD
median range n
NDC
median range n
Tau protein*, pg/ ml 333 97–1,579 71 543 133–1,200 67 130 59–486 41
Aß42**, pg/ml 403 100–1,339 71 382 119–1,011 61 818 485–1,322 41
S-100B protein, ng/ml 2.28 0.83–6.76 59 2.33 0.71–5.18 32 1.87 108–2.82 22
* p ! 0.001 between AD/DLB and NDC and p ! 0.05 between AD and DLB; ** p ! 0.001 between AD/DLB and
NDC.
Results
Tau Protein
Tau protein levels ranged between 97 and 1,579 pg/ml
(median: 333 pg/ml) in the DLB group, between 133 and
1,200 pg/ml (median: 543 pg/ml) in the AD group and
between 59 and 486 pg/ml (median: 130 pg/ml) in the
NDC group (fig. 1). 43 DLB patients showed tau levels
below and 28 showed tau levels above 450 pg/ml.
There were significantly higher levels of tau protein in
the AD and DLB groups compared to the NDC group (p !
0.001). Tau protein levels were higher in the AD group
compared to the DLB group (p = 0.003).
ß-Amyloid(1–42) 
Aß42 levels ranged between 100 and 1,339 pg/ml (me-
dian: 403 pg/ml) in the DLB group, between 191 and
1,011 pg/ml (median: 382 pg/ml) in the AD patients and
between 485 and 1,322 pg/ml (median: 818 pg/ml) in the
NDC group (fig. 1).
Aß42 levels were significantly decreased in AD and
DLB compared to NDC (p ! 0.001). There was no statisti-
cally significant discrimination between AD and DLB by
Aß42 (p = 0.85).
S-100B Protein 
The levels of S-100B protein ranged between 0.83 and
6.76 ng/ml (median: 2.28 ng/ml) in the DLB patients,
between 0.71 and 5.18 ng/ml (median: 2.33 ng/ml) in the
AD patients and between 1.08 and 2.82 ng/ml (median:
1.87 ng/ml) in the control group (fig. 1). S100-B protein
was analyzed in 22 patients of the NDC group: Four
patients with depression showed levels between 1.26 and
2.51 ng/ml (median: 2.14 ng/ml). Five patients with isch-
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Fig. 1. Box plots of tau protein (ng/ml), Aß42 (pg/ml), and S-100B
protein (ng/ml) in CSF of patients suffering from DLB, AD and NDC
() median, g 25–75%, PA
P min–max).
Fig. 2. Tau protein (ng/ml) in patients suffering from AD and DLB
with two core features [1] (DLB-II, n = 23) and with three core fea-
tures (DLB-III, n = 48) () median, g 25–75%, PA
P min–max).
emia had levels between 1.53 and 2.82 ng/ml (median:
2.66 ng/ml). The levels of 5 patients with peripheral neu-
rological disorder varied between 1.08 and 2.51 (median:
2.1 ng/ml). S100B level of the patient with acute psychosis
was 1.37 ng/ml, with myopathy 2.55 ng/ml, with hydro-
cephalus 2.6 ng/ml, neuronitis vestibularis 2.35 ng/ml,
epileptic seizures 1.53 ng/ml, articular rheumatism 1.82
ng/ml, transient myelitis 2.6 ng/ml, and the patient with
alcoholic delirium showed an S100B level of 1.26 ng/ml. 
S-100B neither discriminated between NDC and the
two dementia groups (p = 0.36: AD vs. NDC; p = 0.11:
DLB vs. NDC) nor between AD and DLB (p = 0.699).
Analysis of the Groups according to Clinical
Presentation 
Variation of MMSE and duration of disease between
AD and DLB groups was not significant (p 1 0.05), nor
was the variation of age at the time of lumbar puncture
between AD and DLB (p 1 0.05). Age at the time of lum-
bar puncture was significantly different between the de-
mented groups (AD and DLB) and the NDC group (p !
0.001).
In the group of DLB patients presenting with two core
features (DLB-II, n = 23), tau protein ranged between 99
and 1,579 pg/ml (median: 448 pg/ml). Tau protein levels
in the DLB-III group (patients fulfilling all three main cri-
teria, n = 48) ranged between 97 and 1,104 pg/ml (me-
dian: 324 pg/ml) (fig. 2). Tau protein levels of the DLB-III
group were significantly lower compared to the AD group
(p ! 0.001) but not between DLB-II and AD (p = 0.89).
S-100B and Aß42 levels did not show subgroup-specific
alterations.
In the group of 6 patients with PDD values, tau protein
levels ranged between 195 and 377 pg/ml (median:
235 pg/ml). In comparison, tau protein levels in the group
of 63 patients with ‘probable’ DLB ranged between 97
and 1,579 pg/ml (median: 356 pg/ml). Again S-100B and
Aß42 levels did not show subgroup-specific alterations.
We found slightly higher S-100B levels in the DLB
group with MMSE 118 (mean: 2.4 ng/ml) compared to
the group with MMSE !18 (mean: 2.0 ng/ml). 
168 Dement Geriatr Cogn Disord 2005;19:164–170 Mollenhauer et al.
Analysis of Neuropathologically Verified Cases 
In the CSF of the 2 ‘definite’ DLB cases, tau protein
was 466 and 289 pg/ml, respectively and Aß42 was 542
and 333 pg/ml, respectively. S-100B protein was mea-
sured only in 1 definite DLB case, at 1.62 ng/ml. Both
patients were clinically classified as ‘probable’ DLB and
fulfilled all three core criteria. The 3 ‘definite’ AD cases
presented with tau protein levels between 332 and
1,200 pg/ml and S-100B protein levels between 3.4 ng/ml
and 2.5 ng/ml (Aß42 was not done).
Analysis according to Insulin Medication 
Twelve patients in the DLB group were known to have
diabetes mellitus. Two of these used insulin medication.
Tau protein values for these patients were 259 and
300 pg/ml, and S-100B protein levels were 2.17 and
2.85 ng/ml. Aß42 levels were 704 and 698 pg/ml in the 2
DLB patients with insulin-dependent diabetes mellitus
and ranged between 191 and 795 pg/ml (median: 519 pg/
ml) in the DLB group with non-insulin-dependent dia-
betes mellitus. There were 2 patients with AD and dia-
betes mellitus. One was insulin-dependent. This patient
showed a tau protein value of 667 pg/ml, Aß42 level was
847 pg/ml and S-100B protein was 2.05 ng/ml.
Discussion 
This is the first study in which CSF levels of tau pro-
tein, Aß42 and S-100B protein were analyzed in a larger
group of patients with DLB in comparison with AD
patients. In smaller studies, discrepant laboratory find-
ings for tau protein and Aß42 were found [15–17, 23–26].
In two studies, it was suggested that DLB might be differ-
entiated from AD by tau protein and Aß42 [15, 16]. How-
ever, in both studies no analysis according to clinical core
features was made and, surprisingly, decreases in Aß42
were found in the clinical control group [16]. In our popu-
lation of clinically well-defined DLB and AD patients, the
CSF levels of tau protein discriminated significantly be-
tween AD and DLB and NDC. Aß42 and S-100B protein
in DLB did not differ significantly from the AD group.
We are aware that our study group is mainly based on
clinical diagnoses. Molecular genetic studies have re-
vealed that both AD and DLB share an elevated ApoE4
allele frequency [27]. The analysis of further laboratory
markers might be stratified according to genetic markers.
However, because of the homogeneity of our results, this
might not be necessary for tau protein, Aß42 and S-100B
protein. We included solely patients with enough clinical
information and detailed medical history given by the rel-
atives to classify them as ‘probable’ DLB according to
established criteria.
Up to now, no data have been available on S-100B lev-
els in DLB. In a case report of neurodegenerative demen-
tia, it was shown that S-100B levels correlate positively
with disease progression, possibly due to gliosis, while tau
protein can decrease due to neuronal loss [28].
It has recently been shown that insulin can increase
Aß42 levels in CSF [29], and in fact 3 of our patients who
suffered from insulin-dependent diabetes mellitus had
higher levels of Aß42.
DLB patients often present with extrapyramidal signs
at onset, not only in PDD. The onset of dementia repre-
sents the onset of cortical neuronal damage, which may
apparently lead to the elevation of markers indicating
neurodegeneration (e.g. tau protein). Our findings sup-
port this hypothesis. Massive neuronal loss occurs in
many of the DLB cortical regions to a similar extent to
that seen in AD, in addition to the classical sites of neu-
ronal death in the brainstem, as in PD [30]. Patients with
PD alone without dementia showed tau protein and Aß42
levels comparable to NDC [15, 23]. Our patients with
PDD presented with lower tau-protein levels than DLB
patients. Our group with PDD is certainly too small for a
valid comparison. However, our observation supports the
idea that patients with parkinsonism, visual hallucina-
tions (which may reflect a medication effect) and elevated
CSF levels of tau protein are more likely to be DLB
patients than patients with PD.
All patients of our DLB group exhibited at least two
core features and were classified as having ‘probable’
DLB, but the majority of our patients exhibited all three
core features with fluctuating cognition, spontaneous ex-
trapyramidal signs and visual hallucinations. These DLB
patients showed significantly lower tau protein levels
compared to the AD patients of our group. Reciprocally
74% of our DLB patients with tau protein levels below
450 pg/ml showed all three core features. According to the
literature, in autopsy-proven DLB patients 73% showed
concomitant AD pathology with higher Braak stages (3–6)
and only 27% with lower Braak stages (0–2). The clinical
diagnostic accuracy for these autopsy-proven DLB cases
was higher for patients with low (75%) compared to high
(39%) Braak stage [30–32]. Our patients, fulfilling all
three core criteria (DLB-III), have lower tau levels, where-
as patients with only two or less core features may repre-
sent a group with AD mixed pathology, pronounced neu-
ronal cell loss and therefore higher tau levels. The fact that
tau protein discriminates between our DLB-III group,
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showing all three core features, and AD patients is of low
clinical relevance since e.g. patients with mixed pathology
may also show neuroleptic sensitivity. CSF of DLB pa-
tients with mild tau pathology and with mild neuron loss
will further need to be examined.
Whether or not other markers like phospho-tau and the
analysis of the spectrum of amyloid peptides will help in
this differentiation must be seen in separate studies [26,
33, 34]. We conclude from our results that the value of the
markers measured here for the differentiation of DLB
from AD is limited, but seems to be of differential diag-
nostic relevance for PDD and DLB.
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